Teva Drops Cipla Qvar Inhaler Patent Row Amid FTC Delisting Push

Sept. 19, 2025, 7:07 PM UTC

Teva Pharmaceutical Industries Ltd. reached an agreement to end its patent-infringement lawsuit against Cipla Ltd. over proposed copies of its Qvar RediHaler asthma treatment, a New Jersey federal court filing said.

The agreement, which left the door open for either side to renew allegations, was approved by Judge Stanley R. Chesler in a consent order of dismissal issued Thursday in the US District Court for the District of New Jersey. No further details were provided. Neither Teva nor Cipla immediately responded to requests for comments.

  • Teva sued the Indian generic-drug maker in February 2024 seeking to block its generic of ...


Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.